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Coffin-Lowry syndrome (CLS) is a syndromic form of X-linked mental retardation that is characterized, in male
patients, by psychomotor and growth retardation and various skeletal anomalies. Typical facial changes and specific
clinical and radiological hand aspects exhibited by patients are essential clues for the diagnosis. CLS is caused by
mutations in a gene that is located in Xp22.2 and that encodes RSK2, a growth-factor–regulated protein kinase.
RSK2 mutations are extremely heterogeneous and lead to premature termination of translation and/or loss of
phosphotransferase activity. Surprisingly, among a series of 250 patients screened by single-strand conformation
polymorphism (SSCP) analysis, in whom a clinical diagnosis of CLS was made, no mutations were detected in 66%
(165) of the patients. To determine what proportion of these latter patients have a RSK2 mutation that has not
been detected and what proportion have different disorders that are phenotypically similar to CLS, we have, in
the present article, investigated, by western blot analysis and in vitro kinase assay, cell lines from 26 patients in
whom no mutation was previously identified by SSCP analysis. This approach allowed us to identify seven novel
RSK2 mutations: two changes in the coding sequence of RSK2, one intragenic deletion, and four unusual intronic
nucleotide substitutions that do not affect the consensus GT or AG splice sites. We have also determined the
nucleotide sequence of the promoter region of the RSK2 gene, and we have screened it for mutations. No disease-
causing nucleotide change was identified, suggesting that mutations affecting the promoter region are unlikely to
account for a large number of patients with CLS. Finally, our results provide evidence that some patients have a
disease that is phenotypically very similar to CLS, which is not caused by RSK2 defects. This suggests that there
are defects in either additional genes or combinations of genes that may result in a CLS-like phenotype.
Introduction
Coffin-Lowry syndrome (CLS [MIM #303600]) is a syn-
dromic form of X-linked mental retardation that initially
was independently described by Coffin et al. (1966) and
Lowry et al. (1971) and was definitively distinguished
by Temtamy et al. (1975). Cardinal features of CLS are
growth and psychomotor retardation, characteristic fa-
cial and digital abnormalities, and progressive skeletal
alterations. CLS occurs in all ethnic groups.
Adult male patients typically are of short stature and
exhibit a characteristic coarse face with a prominent
forehead, orbital hypertelorism, downward-slanting
palpebral fissures, epicanthic folds, prominent ears,
thick lips, a thick nasal septum with anteverted nares,
and irregular or missing teeth. Their large and soft
hands with lax skin and tapering fingers are usually a
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strong diagnostic feature. The most frequent skeletal
involvements are delayed bone development, spinal
kyphosis/scoliosis, and pectus carinatum or excava-
tum. Cognitive function may be variably impaired,
but most males are severely affected. Development of
speech is always involved to variable degrees. Features
such as microcephaly, ventricular dilatation, sensori-
neural deafness, seizures, and cardiac defects may be
present but are less frequent. In addition, connective-
tissue abnormalities, such as inguinal hernia, may be
present. A majority of carrier females have only min-
imal findings (e.g., mild facial coarsening, tapering fin-
gers, and obesity) (Hunter et al. 1982; Gilgenkrantz
et al. 1988; Young 1988; Plomp et al. 1995).
Although the clinical diagnosis of CLS is based solely
on the presence of the characteristic physical findings,
clinicians trained in genetic disorders can often make
the diagnosis in adult patients. Recognition of CLS in
young children is more difficult, since physical char-
acteristics are generally mild and less specific. Affected
newborn males usually show only hypotonia and hy-
perlaxity of joints. Retardation of growth and psycho-
motor development appear gradually in the first years
of life. Facial coarsening, which is mild and hard to
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detect in infancy, becomes progressively pronounced
and characteristic only in late childhood or adolescence
(Wilson and Kelly 1981; Plomp et al. 1995).
We have demonstrated that CLS is caused by loss-
of-function mutations in the gene that encodes RSK2
(ribosomal S6 kinase 2), a serine/threonine kinase from
the family of MAPK (mitogen-activated protein kinase)
activated protein kinases (Trivier et al. 1996). The cod-
ing region of the RSK2 gene, which maps to Xp22.2,
is split into 22 exons (Jacquot et al. 1998) and encodes
a 740-amino-acid protein. We have previously shown
that this gene is subject to strong allelic heterogene-
ity, with 170 different mutations so far identified (see
Coffin Lowry Syndrome Mutations Data Base). These
changes are scattered, without any clustering, through-
out the coding region, and most are family specific; they
include single-base-pair substitutions that cause amino
acid changes, premature stop codons, splice defects,
and small insertions and deletions that result in frame-
shifts (Delaunoy et al. 2001). Unexpectedly, mutations
have been identified in only 34% of individuals with a
clinical diagnosis of CLS who were referred for muta-
tion screening. There are several possible explanations
for the failure to detect mutations in such a high pro-
portion (66%) of patients, and it is likely that more
than one of these explanations needs to be invoked to
explain the discrepancy. It may be related to the known
limitations of SSCP analysis, which was almost exclu-
sively used in the mutation screening (Orita et al. 1989).
TheRSK2 gene may also contain mutations in sequences,
such as the promoter region or introns, that have not
been screened. In addition, it is possible that some of
the patients were atypical and that a misdiagnosis thus
had been made. Nevertheless, detailed clinical records
could be obtained for a number of individuals, provid-
ing evidence that some patients without an RSK2 mu-
tation do indeed exhibit a typical CLS phenotype. There-
fore, a further possibility is that mutations in a gene (or
genes) distinct from RSK2may give rise to a disorder (or
disorders) phenotypically very similar to CLS.
Mutations in the RSK2 gene that have so far been
found result in truncated proteins, not detectable on
western blot with the currently available antibodies,
and/or a dramatically reduced RSK2 phosphotransfer-
ase activity, when tested in an in vitro S6 kinase assay
(Trivier et al. 1996; Merienne et al. 1998). Together,
these two assays are expected to detect all classes of
mutations and, in particular, all those classes that either
are not detectable by SSCP analysis or may affect the
level of transcription. Therefore, in the present article,
we have further investigated, by western blot analysis
and in vitro kinase assay, cell lines from 26 unrelated
patients in whom no mutation was previously identified
by SSCP analysis. Although some of these patients ex-
hibited additional features not commonly associated
with CLS, all had physical findings that were charac-
teristic of CLS. This approach allowed us to identify
seven patients who carry RSK2 mutant proteins. The
nature of the mutations has been determined. Addi-
tionally, we have determined the nucleotide sequence of
the promoter region of the RSK2 gene, and we have
screened it for mutations. No disease-causing nucleotide
change was identified. Importantly, our results provide
evidence that some patients have a disease that is phe-
notypically very similar to CLS but is not caused by
RSK2 defects. This suggests that defects in other genes
may result in a CLS-like phenotype.
Patients and Methods
Patients
Twenty-six unrelated patients with the diagnosis of
CLS and from whom a cell line was available were in-
cluded in this study. They were referred by 18 different
European and American pediatricians or clinical genet-
icists, and no mutations were detected by SSCP analysis,
as described elsewhere (Jacquot et al. 1998; Delaunoy
et al. 2001). A detailed clinical questionnaire (completed
by the clinicians), for each patient, and photographs, for
two-thirds of the patients, were available for review. All
of these patients exhibited clinical features highly sug-
gestive of CLS (table 1).
Cell Culture
Patient lymphoblastoid cell lines were grown in
Roswell Park Memorial Institute 1640 medium sup-
plemented with 10% fetal calf serum. Fibroblast cell
lines were grown in Dulbecco modified Eagle medium
supplemented with 10% fetal calf serum.
Western Blot Analysis
Pellets from confluent lymphoblastoid and fibroblast
cell lines were washed once with ice-cold PBS and were
resuspended in 500 ml cold NP40 lysis buffer (50 mM
Tris-HCl, with pH 7.4; 1% NP40; 0.5% Triton 1-100;
150 mM NaCl; 1 mM EDTA; 1 mM Na3VO4; 1 mM
phenylmethylsulfonyl fluoride; and 1# protease in-
hibitor cocktail). After 30 min on ice, the lysates were
centrifuged for 15 min at 13,000 rpm at 4C. The pel-
lets were discarded, and the protein content of the su-
pernatants was determined using the BIO-RAD protein
assay (BioRad). The cell lysates (100 mg total protein)
were resolved by standard SDS/6% PAGE. After 1 h
transfer to Protran nitrocellulose membranes (Schlei-
cher and Schuell), the RSK2 protein was detected with
the mouse monoclonal E1 antibody (Santa Cruz Bio-
technology), which was raised against the C-termi-
nus of the human RSK2 protein. The amount of ERK2
protein, used as an internal control, was determined
Table 1
Clinical Data
CHARACTERISTIC
DATA FOR PATIENT
AD57 CV59 EZ48 DZ75 GW55 GW87 DZ91 DX43 DX55 DX86 DZ32 DZ36 DZ37 EZ14 FP41 FP67 GM10 GM48 GM49 GM98 GW11 GW15 GW24 GW44 GW85 MH55
RSK2 mutation                          
Age at examination (years) 21 10 7 7 12 30 5 20 35 29 38 40 18 9 3 1 6 9 10 13 13 11 12 1 28 10
Neurological:
Mental retardation S Mi Mo S S S Mo Mo S S Mo S S S S S S S S S S S Mi S S Mo
Developmental delay                          
Speech delay                          
Hypotonia      …     …               
Ventricular dilatation … …   …  … … …  … … … … …  … … … …   …   …
Sensorineural hearing deficit      … …  …     …   …         
Seizure    … … … …       …  … …   … … …  …  
Drop attacks     …  …   … …   …  … … … … …     … …
Growth:
Small stature    …                   …   
Stooped posture …  … … …  …  …     … … …    …   …  … …
Facial features:
Microcephaly …  … … … … …  …  …  … … …  … … …    …  … 
Broad nose                          
Anteverted nares                          
Large ears …  … … …  …  …    … …   …      …  … 
Hypertelorism                          
Downward-slanting palpebral
fissures                          
Thick/everted lips                          
Large mouth   …   …                    
Frontal bossing                          
Maxillary hypoplasia …  …     … … …       …  …     … … …
High vaulted/narrow palate … … …  …   … … …  … …  … … … …  … … …   … 
Limbs:
Large, soft hands   … …         …  … … …         …
Short, puffy, tapered fingers                          
Hyperextensible joints      … … …  … …   … …   …     …   
Transverse hypothenar crease  … … … …  … … … … … … … … … … … … … … … … …  … 
Forearm fullness …  … … … … … …    … … … … … … … … … … … …  … 
Flat feet  … … …   … …   … …   … … …   …   …   
Thorax:
Pectus carinatum/excavatum …  … … … … …  …  …     … …   … … …  … … …
Kyphosis/scoliosis   …    …         … … …   … …   … 
Cardiac:
Mitral regurgitation    … … … … … …    …  …    … …  …  …  …
Teeth:
Anodontia/oligodontia    …             …    … …  …  
Abnormal dental position       …      …    … …  … … …  …  
Radiology:
Drumstick terminal phalanges   …      …    … …            
Retarded bone age … … … …   …  …   … … … …  … … …     …  
Ligamenta flava calcification  … … … …  … … … … … … … … … … … … … … … … … … … …
Narrow intervertebral spaces  … … … … … … … …  … … … … … … … … … … … … …  … …
Anterior vertebral body defect … … … … … … … … …  … … … … … … … … … … … … … … … …
Thickened skull … … … … … … … … …  … … … … … … … … …  … … … … … …
Other features:
Hernia … …  … … …  … … …  … …  …  … … … …  …  …  …
Obesity … … … … …  … … … … … … … … … … … … … … … … … … … 
Autism … … … … … … … … … … … … … … … … …   … … … … …  …
Expression in mother: MM NM NM NM MM NM NM MM MM NM … NM MM … NM NM MM MM MM NM MM … … MM NM NM
NOTE.— p Positive;  p negative; S p severe mental retardation, Mi p mild mental retardation; Mo p moderate mental retardation; MM p mild manifestation; NM p no manifestation; ellipses indicate that no data were available.
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using the rabbit polyclonal anti-ERK2 K-23 antibody
(Santa Cruz Biotechnology). Final detection was done
by chemiluminescence by use of the Super Signal West
Pico Stable Peroxide Solution (Pierce).
S6 Kinase Assay
The RSK2 protein was immunoprecipitated from pro-
tein extracts (1 mg total protein), by incubation for 2 h
at 4C with the rabbit polyclonal C-19 antibody (Santa
Cruz Biotechnology), which was directed against the C-
terminus of the human RSK2 protein. After incubation
for 30 min with protein G sepharose, the immunoprecip-
itates were washed three times with NP40 lysis buffer and
once with kinase assay buffer (20 mM 3-(N-Morpholino)
propanesulfonic acid, with pH 7.2; 25 mM b-glycerol
phosphate; 5 mM ethyleneglycoltetraacetic acid; 1 mM
Na3VO4; and 1 mM dithiothreitol). The amounts of im-
munoprecipitated RSK2 protein were subsequently quan-
tified on western blot, and quantities were normalized
before performing an S6 kinase assay (S6 kinase assay
kit; Upstate Biotechnology), as described elsewhere (Mer-
ienne et al. 1998). Five lymphoblastoid (from patients
AG96, AZ21, CN14, DX6, and DX57) and four fibro-
blast (from patients CV59, DX34, DZ57, and MC9) cell
lines were used as negative controls. Patients AG96,
CN14, DX6, DZ57, and MC9 carry missense mutations
(S227A, G75V, T231I, R383W, and I189K) that were
shown to abolish or dramatically decrease the RSK2 ki-
nase activity (Trivier et al. 1996; Merienne et al. 1998;
Delaunoy et al. 2001). S227A, T231I, and R383W affect
phosphorylation sites that are critical for RSK2 catalytic
function, and G75V affects the N-terminal ATP binding
site. I189K is likely to disrupt the secondary structure of
the N-terminal kinase domain (Delaunoy et al. 2001). An
intragenic deletion that encompasses exons 6 and 7 of
the RSK2 gene and results in a truncated nonfunctional
protein was identified in patient AZ21. The remaining
patients (DX57, CV59, and DX34) carry splice-site mu-
tations (IVS6-1 GrA, IVS43 insT, and IVS142 TrC,
respectively) (Trivier et al. 1996; Delaunoy et al. 2001).
All of them result in truncated nonfunctional RSK2
proteins.
RT-PCR Analysis and Exon-Skipping Detection
RNA was extracted from cell lines by use of the
RNA-Solv reagent (Omega Biotek). The first-strand
cDNA was synthesized using both random hexa-
mers and oligo-dT as primers. The primers used for
PCR amplification were designed from the RSK2
cDNA sequences (Bjorbaek et al. 1995), with for-
ward primers 5′-TGGCGCAGCTGGCGGA-3′, 5′-
GATGTTCACAGAAGAAGAT-3′, 5′-ACCTCAGAT-
GATGAAAGC-3′, 5′-GGAGGTGAATTGCTGGAT-
AAAA-3′, and 5′-GCTATGATGCTGCTTGTGAT-3′
and reverse primers 5′-ATTATTCCCAGGCTATG-
TAG-3′, 5′-GCTTTCATCATCTGAGGT-3′, 5′-AGT-
TATAGTGAACAGGACAG-3′, 5′-GTATCATCAGG-
ACCATTTGC-3′, and 5′-CAAATATCTCACTGAG-
GTCAC-3′.
PCRs were run for 35 cycles, and PCR products were
resolved on 2% agarose gels. Electrophoretic variants
were sequenced from both the forward and the reverse
strands, after PCR products had been purified with the
NucleoSpin Extract 2 in 1 kit (Macherey-Nagel).
Mutation Detection
Genomic DNA was extracted from patient cell lines
for which exon skipping was observed. The exon or
exons skipped, as well as the exons preceding and fol-
lowing, were PCR amplified using flanking intronic
primers (Jacquot et al. 1998). The PCR products were
sequenced after purification with the NucleoSpin Extract
2 in 1 kit (Macherey-Nagel). Exonic mutations were
identified after direct sequencing of the RT-PCR prod-
ucts obtained as described above.
Promoter Sequence
The promoter sequence of the human RSK2 gene was
obtained after subcloning in a cosmid and direct se-
quencing of an EcoRI genomic fragment that contains
2,000 bp of sequence upstream from the translation
start site.
Localization of the Transcription Start Site by RT-PCR
RNA from control lymphoblastoid cell lines was pre-
pared as described above. RNA extraction was followed
by 1 h DNase I treatment at 25C. The first-strand cDNA
was synthesized using reverse primers 5′-AGCAGCAGC-
AGCAGCGGC-3′ and5′-TCCGTCCCGCCCGAGCC-3′.
For PCR amplification, the primers used were as follows:
forward primers 5′-GCGGAAGGAGGAGAGGAA-3′, 5′-
CCGGTGCCCAGCGGAGGC-3′, 5′-GCGCGAGGCTC-
TCGCTCA-3′, 5′-CTGTTTCTTCTGGGAGCGG-3′, and
5′-AGAGGGAGGAGCGGAGCG-3′ and reverse primer
5′-AGAGGGCTCGACGCCGAC-3′. PCRs were run for
35 cycles. The PCR products were resolved on 2% aga-
rose gels.
Primer Extension
The primers used were as follows: 5′-ACGCCGACG-
CCGACCGCCCGAAAGCCGCGC-3′ and 5′-GCTCG-
ACGCCGACGCCGACCGCCCGAAAGC-3′. One hun-
dred thousand counts per minute 32P-labeled primer was
hybridized to 30 mg total RNA, prepared as described
above, from control lymphoblastoid cell lines. Reverse
transcription was performed for 1 h at 42C by use of
the reverse transcriptase AMV (Boehringer Mannheim).
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Table 2
Western Blot Results on Extracts from 26
Independent Patient Cell Lines
Patient Cell Linea RSK2 Proteinb
AD57 F 
CV59 F 
DX43 L 
DX55 F 
DX86 L 
DZ32 L 
DZ36 L 
DZ37 L 
DZ75 L 
DZ91 L 
EZ14 L 
EZ48 L 
FP41 F 
FP67 L 
GM10 L 
GM48 L 
GM49 L 
GM98 L 
GW11 L 
GW15 L 
GW24 L 
GW44 L 
GW55 L 
GW85 L 
GW87 L 
MH55 L 
a F p fibroblast cell line; L p lymphoblastoid
cell line.
b  p Present;  p absent.
Figure 1 Western blot analysis of endogenous RSK2 (top) and
ERK2 (bottom) proteins from lymphoblastoid (A) or fibroblast (B) cell
lines, established from patients and controls. The origin of the cell line
is indicated. Positive control cell lines shown are from patients BZ49
and 34226; negative control cell line shown is from patient AZ21.
Three (patients DZ75, EZ48, and CV59) of the seven patients inwhom
the full-length RSK2 protein could not be detected are shown.
The reaction products were subsequently resolved on
6% denaturing polyacrylamide gels and revealed by
autoradiography.
Prediction of Transcription-Factor Binding Sites
For the search of consensus DNA elements involved
in the regulation of gene expression, the following pro-
grams were used: MatInspector V2.2 (based on TRANS-
FAC 4.0) and Transcription Element Search (TESS).
Promoter-Region Mutational Analysis by SSCP
Genomic DNA was obtained from 66 independent pa-
tients with a clinical diagnosis of CLS and from controls.
The promoter region of theRSK2 genewas PCRamplified
using four distinct sets of primers (forward primers 5′-
CGCAGTGAACACAGGGTCGAGT-3′, 5′-ACCTCCC-
TGTTTTCCCCTCTTGA-3′, 5′-TACTTTGCCCACCT-
CCCT-3′, and 5′-GGGGGTGGGAAGAGGGAG-3′ and
reverse primers 5′-TAAGGAAACCCAATGCCCCGAC-
3′, 5′-CTCCTGGGGGCTCGGCTC-3′, 5′-CTCCGCTC-
CTCCCTCTTC-3′, and 5′-TCTCCTCCTTCCGCCGC-
C-3′). PCR products were analyzed by SSCP on PlusOne
precast acrylamide gels (Pharmacia) with a Genephor
electrophoresis device (Pharmacia), at two different run-
ning temperatures (5C and 15C). Electrophoretic var-
iants were sequenced from both the forward and the
reverse strands, after PCR products had been purified
as described above. Presence or absence of mutations
was tested by SSCP on control DNA from the respective
populations.
Results
Western Blot Analysis and Identification
of Seven Novel RSK2 Mutations
A series of 26 patients who exhibit features highly
suggestive of CLS (table 1) and from whom lympho-
blastoid or fibroblast cell lines were available were an-
alyzed by western blot. For all these patients, previous
SSCP analysis failed to detect any obvious abnormality
in the coding region of the RSK2 gene. However, an
intragenic deletion was suspected in patient GW55, be-
cause of the failure to PCR amplify exon 18.
No RSK2 protein was detectable in 7 of the 26 pa-
tients analyzed (table 2). Three of the patients (DZ75,
EZ48, and CV59) are shown in figure 1. The amount
of ERK2, which was used as an internal control, was
roughly the same in all the patients tested, as well as in
positive and negative control subjects (for the same type
of cell line), which excluded protein degradation in the
negative samples. RNA was extracted from the seven
cell lines, and RT-PCR products, covering the whole hu-
man RSK2 cDNA, were directly sequenced. This re-
vealed the presence of transcripts internally deleted in
four individuals (fig. 2). In patient DZ75, skipping of
either exon 10 alone or both exons 9 and 10 was ob-
served, whereas, in patients CV59, GW87, and GW55,
skipping of only one exon (exons 4, 6, and 18, respec-
tively) was evident. The exon organization of the RSK2
coding sequence predicts that all but one (in patient
GW55) of these defects results in the alteration of the
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Figure 2 Abnormal transcripts identified by RT-PCR analysis in patients without detectable RSK2 protein. Plus signs () indicate the
presence of the indicated exon(s), and minus signs () indicate the absence of the indicated exon(s). A, Absence of exon 4 in patient CV59. B,
Skipping of exon 5 (lower band) and insertion of an additional 10 bp between exons 4 and 5 (upper band), in patient EZ48. C, Absence of exon
6 in patient GW87. D, Absence of either exon 10 (upper band) or both exons 9 and 10 (lower band), in patient DZ75. E, Absence of exon 18 in
patient GW55.
reading frame, which leads to the introduction of a pre-
mature termination codon. Since the E1 antibody is di-
rected against the carboxyl-terminus of RSK2, detection
of truncated proteins is not expected, if the latter is pres-
ent; this explains the absence of signal on western blot.
Patient EZ48 showed two aberrant RT-PCR fragments,
which were 10 bp larger and 81 bp smaller than expected
(fig. 2). Direct sequencing of these fragments revealed
that the larger fragment represents an alternatively
spliced mRNA product in which a cryptic splice site, 10
bp upstream from the normal IVS4 acceptor splice site,
has been used. The insertion of an additional 10 bp
between exons 4 and 5 is predicted to cause a frameshift
with premature termination in exon 5. The smaller frag-
ment represents the skipping of exon 5. In both patients,
EZ48 (for the smaller fragment) and GW 55, skipped
exons (exons 5 and 18, respectively) are in frame. Ab-
sence of signal on western blot in those latter cases is
probably due to instability of the resulting proteins.
Skipped exons, as well as preceding and following ex-
ons and respective surrounding intronic regions, were se-
quenced after PCR amplification of genomic DNA from
the patients (fig. 3). This allowed us to identify four in-
tronic mutations, including IVS63 ArG in patient
GW87, IVS43 insT in patient CV59, and IVS105
GrA in patient DZ75; the fourth intronic base-pair
change, IVS5-11 ArG, was observed in patient EZ48. In
all these patients, no other sequence abnormality was ob-
served, indicating that these changes are indeed respon-
sible for the splicing defects observed. Sequencing of RT-
PCR products from patient GW55 revealed absence of
exon 18 in theRSK2mRNA.Wewere unable, repeatedly,
to amplify exon 18 with flanking primers from genomic
DNA from this patient, suggesting that an intragenic de-
letion encompasses exon 18 and at least part of intronic
sequences surrounding this exon. This was confirmed by
subsequent Southern blot analysis (not shown). Direct
sequencing of the RT-PCR products from patients AD57
and DZ91 revealed the presence of mutations in the cod-
ing region of the RSK2 gene. A single-nucleotide insertion
in exon 4 (262 insA), resulting in a frameshift, was found
in patient AD57. Patient DZ91 carried a missense mu-
tation in exon 21 (1964 TrC), resulting in the substi-
tution of a leucine by a proline residue (L655P).
All the patients in whom the RSK2 proteinwas present
at normal levels were further investigated using the S6
kinase assay (fig. 4). Negative controls included patients
with CLS with already characterized RSK2 mutations,
which resulted either in a dramatic decrease of the RSK2
kinase activity—since they affect the catalytic domains,
the ATP binding sites, or the regulatory domains of the
protein—or in truncated nonfunctional RSK2 proteins
(Delaunoy et al. 2001).
Of the 19 patients tested, 4 (patients DZ36, DZ37,
GM98, andMH55) presented reduced but not abolished
RSK2 kinase activity (fig. 4). However, after RNA ex-
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Figure 3 RSK2 sequence variants in seven patients with no detectable RSK2 protein. Wild-type (top panels) and mutant (bottom panels)
sequences are shown. Arrows indicate the site of mutation. The mutations identified are indicated below the lower panels. Forward sequences
are given for all patients except patient EZ48.
traction from the lymphoblastoid cell lines that were
established from these patients and direct sequencing of
RT-PCR products, we could not find any abnormality
in the coding region of the RSK2 gene.
In some patients, a higher RSK2 kinase activity was
found, when compared to positive controls (fig. 4). In
all these patients, levels of RSK2 protein as determined
by western blot analysis were very similar to those of
normal control individuals. In addition, semiquantita-
tive RT-PCR analysis failed to reveal higher levels of
RSK2 mRNA (not shown) in these patients. Together,
our results exclude the possibility of duplication of the
RSK2 gene in any of these patients, and direct sequenc-
ing of the entire RSK2 cDNA in two of the patients
(GW11 and GW85) failed to identify any sequence
abnormality.
Study of the Promoter Region of the Human RSK2
Gene
Our results confirm that, for the RSK2 gene, as ex-
pected from results for other genes, some mutations
(mostly intronic ones) are missed by SSCP analysis. How-
ever, this cannot fully explain our incapacity to identify
mutations in such a large number (66%) of patients in
whom CLS features were diagnosed. This prompted us
to explore the possibility of mutations in the promoter
region of the RSK2 gene. Mutations that affect transcrip-
tion of the RSK2 gene in lymphoblasts or fibroblasts are
expected to be detectable by western blot analysis. How-
ever,mutations thatwould affectRSK2protein expression
in other cell types would be missed by such analysis.
Since the nucleotide sequence of the promoter region
was not yet known, we have determined the sequence
of a region of 2,000 bp upstream from the translation
start site (fig. 5). To identify the transcription initiation
site, we performed RT-PCR experiments on RNA from
a human lymphoblastoid cell line, in which the gene is
well expressed. Our results indicated that the start site
of transcription is located between positions 452 and
297, with respect to the first nucleotide of the trans-
lation initiation codon, which has been denoted as “1.”
Indeed, using a primer starting at position 297, we
were able to amplify a fragment of the expected size,
whereas, using a primer starting at position 452, we
obtained no amplification product (not shown). Primer-
extension experiments allowed us to precisely identify
the transcription initiation site; it is located at the first
guanosine of the sequence 5′-GCGGTC-3′, at position
361 (fig. 5). This is in agreement with the results ob-
tained by RT-PCR. The 5′-flanking region of the RSK2
gene is particularly (78%) GC rich. In addition, no iden-
tifiable CAAT-box or TATA-box motifs were found im-
mediately upstream from the transcription initiation site.
These features are common to the regulatory sequences
of housekeeping genes. This is in agreement with the
observation of ubiquitous expression of the RSK2 gene
(A.H., unpublished results).
To identify putative cis-acting transcription-factor
binding sites, we searched sequences spanning positions
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Figure 4 RSK2 enzymatic activity in 19 patients. RSK2 was immunoprecipitated from equal amounts of total proteins derived from
lymphoblastoid or fibroblast cell lines from patients who presented normal levels of RSK2 protein on western blot. The values obtained for
positive and negative controls (C and C, respectively) in lymphoblastoid and fibroblast cell lines were comparable. Data are represented as
the percentage of the mean specific RSK2 activity immunoprecipitated from four wild-type lymphoblastoid and two wild-type fibroblast cell
lines (C; wild-type relative–specific activity ). Negative controls (see “Patients and Methods”) included five lymphoblastoid and100% 26%
four fibroblast cell lines (C; mean value ). Experiments were repeated at least three times with independently prepared cell13.8% 13.3%
extracts. The limit lines associated with each bar represent the SD from the mean value for all experiments.
1800 to 1, with both the MatInspector program and
the TESS program. Several Sp-1 binding sites were pre-
dicted by both programs, in agreement with the GC-rich
nature of the promoter region. Additional putative con-
sensus motifs identified include a c-Ets-1 binding site, a
Pu-box normally bound by the Ets-family macrophage-
specific factor PU.1, as well as binding sites for factors
such as AP-4, AP-2, E2A, the glucocorticoid-receptor/
prolactin-receptor dimmer, and the estrogen receptor.
However, further functional studies are necessary to
determine whether these motifs have a physiological
relevance.
Search for Mutations in the Promoter Region
of the Human RSK2 Gene by SSCP Analysis
Four distinct regions located in the promoter of the
RSK2 gene were amplified by PCR from genomic DNA
extracted from the cell lines in which no RSK2mutation
has been found. In addition, blood-extracted genomic
DNA from 47 independent patients diagnosed with CLS
for whom previous SSCP analysis failed to identify a
mutation in the coding region of the RSK2 gene was
also analyzed. Promoter regions that were screened con-
tain putative transcription-factor binding sites and/or the
transcription start site. SSCP analysis of the resulting
fragments revealed two rare polymorphisms: one at po-
sition 1140 (C instead of T) and one at position320
(C instead of G) immediately upstream from a predicted
Sp-1 binding site. The first polymorphism was observed
in patient DZ75 and on 1 of 88 normal control X chro-
mosomes tested; the second polymorphism was found
only in patient DZ32 but not in 134 normal control X
chromosomes tested. Semiquantitative RT-PCR experi-
ments failed to show reduced RSK2 mRNA expression
in the lymphoblastoid cell line derived from this patient
(not shown). In addition, western blot analysis and S6-
kinase-assay tests revealed normal levels of RSK2 pro-
tein and normal RSK2 phosphotransferase activity (figs.
1 and 4). No other type of cell line is currently available
from this patient. Together, these results suggest that this
latter nucleotide change may be a rare polymorphism
and not a disease-causing mutation.
Discussion
We have shown previously that CLS is caused by loss-
of-function mutations in the RSK2 gene. On the basis
of current knowledge on the nature of RSK2 mutations,
it can be estimated that western blot analysis allows
detection of up to 70% of the mutated RSK2 proteins
(Delaunoy et al. 2001). Most of the remaining RSK2
mutations are missense changes that have been shown
to result in partial or complete loss of RSK2 phospho-
transferase activity when tested in an in vitro S6 kinase
assay (Trivier et al. 1996; Merienne et al. 1998). In the
present article, we have further investigated the efficiency
of western blot analysis and kinase assays as tools in the
diagnosis of CLS, as well as the proportion of patients
with RSK2 deficiency that have not been detected by
SSCP analysis. Another important issue that we wanted
to address is the possible genetic heterogeneity in CLS.
Western blot analysis revealed absence of the full-
length RSK2 protein in approximately one-fourth (27%)
of the patients included in this study. More than half
of the mutations subsequently identified are found in
intronic regions and do not affect the consensus GT or
Figure 5 Characterization of the 5′ end of human RSK2. A, Representation of the 5′ sequence from RSK2. The transcriptional
start site is indicated in boldface, at position 361; the translational start site (ATG with A at position 1) and coding sequence for
human RSK2 are denoted in boldface. Underlined sequences correspond to putative cis-acting transcription-factor binding sites, as
predicted by the MatInspector and TESS programs. B, Determination of the transcriptional start site. Two distinct 30-mers were elongated
by primer extension and were resolved along with a sequencing ladder. The transcriptional start site was determined relative to the
length of the resulting fragments.
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AG splice sites. Thus, even if they had been identified
by SSCP analysis, further investigations—such as RT-
PCR, which cannot be performed easily in a routine
diagnostic laboratory—would have been necessary to
determine whether they affect normal splicing. Inter-
estingly, two of these mutations are quite unusual:
1. To our knowledge, an ArG transition at position
3 of a 5′ donor splice site (as had been observed in patient
GW87) has been documented in only a small number
of human disorders (Ohno et al. 1999; Park et al. 2000).
This mutation, which results in skipping of the nearby
exon, is puzzling because both A and G nucleotides are
commonly observed at position 3 of native splice-donor
sites in human (Ohno et al. 1999).
2. In patient EZ48, we observed an ArG transition
at position11 upstream from exon 5, creating a cryptic
acceptor splice site which is preferentially used. Indeed,
we believe that the low visible amount of the resulting
transcript on the gel is due to degradation by nonsense-
mediated mRNA decay. In somemolecules, themutation
leads to skipping of exon 5.
Both of these mutations are currently being further in-
vestigated to determine the mechanisms that lead to
these intriguing aberrant-splicing events. Patients CV59
and DZ75 bear mutations that affect the donor splice
sites downstream from exons 4 and 10 (i.e., IVS43
insT and IVS105 GrA), respectively, thereby lead-
ing, in both cases, to complete skipping of the nearby
exon(s).
The high proportion of four splicing aberrations in a
total of seven mutations that have been identified in this
study is noteworthy. Abnormal mRNA splicing does
indeed represent a relatively common mechanism in the
pathogenesis of CLS. Altogether, splice-site mutations
account for 24% of all mutations so far identified in
patients with CLS, which is much higher than the 10%
that can be calculated when taking into account all the
gene mutations that are listed in the Human Gene Mu-
tation Database (Krawczak and Cooper 1997).
Interestingly, we were able to identify two patients
who carried mutations in the coding region of the
RSK2 gene that were not detected by SSCP analysis.
Patient AD57 carried a frameshift mutation in exon 4
(262 insA), and patient DZ91 carried a missense mu-
tation (1964 TrC) in exon 21 that lead to the sub-
stitution of a leucine residue by a proline residue at
codon 655. Since the RSK2 protein is not detectable
by western blot analysis in the latter case, we assumed
that the L655P missense mutation affects the structure
of the RSK2 protein, thereby leading to its instability.
This is the first instance of a missense mutation in the
RSK2 gene that results in lack of the RSK2 protein.
However, missense mutations that lead to unstable
proteins have already been described in other genetic
disorders (Laporte et al. 2000).
Finally, patient GW55 carries a genomic deletion that
encompasses exon 18 and at least part of the surround-
ing introns. Only two large deletions had previously
been identified in the RSK2 gene (Delaunoy et al. 2001),
thus making this the third such deletion.
Cell lines from 19 patients who showed normal levels
of RSK2 protein by western blot analysis were subse-
quently assayed for RSK2 phosphotransferase activity.
None of the patients presented a dramatically reduced
RSK2 activity. Mutations that affect RSK2 catalytic do-
mains, regulation sites, or the ERK binding site have been
shown to be constantly associated with either complete
loss or up to 80% loss of enzymatic activity (Trivier et
al. 1996; Merienne et al. 1998, 1999; Manouvrier et al.
1999). These results have indicated that the S6 kinase
assay is capable of detecting with confidence more than
80% of reduction of kinase activity. Thus, it is unlikely
that patients studied in the present article carry such se-
vere mutations. Some patients (DZ36, DZ37, GM98,
and MH55) showed diminished, although not dramat-
ically reduced, kinase activity. Importantly, cDNA se-
quencing did not identify any mutations in the RSK2
gene, and western blot analysis showed normal levels of
protein expression in these patients. In addition, no nu-
cleotide change was found in the promoter region. We
speculate that these patientsmay carrymutations in genes
that are distinct from RSK2 and encode proteins that,
for instance, act upstream from RSK2 in the signaling
pathway or are involved in the regulation of the RSK2
enzymatic activity. However, as yet, no mutations in such
known genes have been found to be associated with a
CLS-like phenotype. Fibroblast cell lines from these pa-
tients will be available in the near future, and their avail-
ability will allow the confirmation of the results in a
different cell type and the further investigation of the
MAPK-RSK2 pathway.
Finally, duplication of the RSK2 gene was excluded
in some patients with slightly increased levels of RSK2
kinase activity. Direct cDNA sequencing excluded the
presence of mutations in two of these patients (GW11
and GW85).
Our data suggest that a mutation that results in a
50% decrease of kinase activity would be difficult
to detect by use of the current protocol. Growth of
Epstein-Barr virus–transformed lymphoblastoid cells
is highly variable from one cell line to another and
even from one experiment to another. In addition, the
MAPK pathway and RSKs have been implicated in cell
proliferation and cell-cycle control. This may explain
the variations observed in the levels of kinase activity
(for equal amounts of RSK2 protein) (fig. 4). Experi-
ments with nontransformed (i.e., primary) fibroblast
cell lines (which can be stimulated with growth factors
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such as EGF [epidermal growth factor]) and some
modifications of the protocol are ongoing, to try to
improve this assay. No consistent relationship has been
observed between specific mutations and the severity
of the disease (Jacquot et al. 1998). Nevertheless, we
have observed that there is a tendency for some pa-
tients who carry missense mutations that leave residual
enzymatic activity to be less severely affected. The less
severely affected male patient in the cohort with CLS
that we studied expressed a mutant protein that retains
20% of residual kinase activity. This patient did not
exhibit any of the facial, digital, and skeletal features
of CLS, and his cognitive function was only mildly
impaired (Merienne et al. 1999). Thus, together, our
current data suggest that only very mild cases, which
may not even currently be recognized as CLS on the
basis of clinical examination, would probably be
missed by the S6 kinase assay.
Indeed, our results confirm that western blot analysis
of RSK2 is a very efficient, reliable, and rapid assay and
allows confirmation of the diagnosis in most patients
with CLS. Moreover, as indicated by the present data,
even patients who carry some missense mutations may
be detected by immunoblot analysis. Thus, this assay
may be a very useful prescreening test for CLS, in med-
ical practice. We have previously shown that the RSK2
protein can be detected using lymphocyte-protein ex-
tracts that were prepared directly from fresh blood sam-
ples (i.e., those extracted within 24 h) (Merienne et al.
1998). In addition, western blot analysis can be used
for prenatal diagnosis, since the RSK2 protein is readily
detectable in cultured amniocytes (Jacquot et al. 2002).
Use of the kinase assay as a routine test is more ques-
tionable. It would certainly be the diagnostic method
of choice, since it potentially detects all classes of mu-
tations; however, it can be used only on either cultured
fibroblasts or a lymphoblastoid cell line, and, given our
previous (Merienne et al. 1998) and present results, it
would probably detect with confidence only dramatic
decreases of enzymatic activity. Therefore, we suggest
that this test should be performed only for patients with
typical CLS features in whom the western blot analysis
reveals a normal level of RSK2 protein.
We have cloned and sequenced the human RSK2 pro-
moter region. It has been shown that the RSK2 protein
is expressed in a wide variety of tissues in human and
mouse. However, it is expressed at much higher levels
in skeletal muscle, heart, and pancreas (A.H., unpub-
lished results), suggesting that the RSK2 gene may be
differentially regulated in a tissue-specific manner. Con-
sistent with the broad tissue expression, the RSK2 prox-
imal promoter region has the typical features of a house-
keeping gene. It lacks canonical TATA and CAAT boxes
but exhibits several GC boxes, which are potential bind-
ing sites for ubiquitous transcription factors such as
NFkB and Sp1. Interestingly, also putative Ets binding
sites have been identified. Further studies will be re-
quired to determine if these motifs have a functional
significance. Analysis of the RSK2 putative promoter
region, in 66 patients, revealed only two very rare poly-
morphisms. This result makes it unlikely that mutations
in the promoter region could account for a high number
of patients.
The hypothesis of additional exons not yet discov-
ered, resulting from alternative splicing, which would
contain the missing mutations is also very unlikely.
BLAST screening of human and mouse EST databases
does not reveal any RSK2 ESTs with additional still-
unknown sequences. In addition, western and northern
blot analysis in various mouse tissues (S. Jacquot and
A.H., unpublished results) do not provide any sugges-
tion of alternative splicing.
No RSK2 mutation has been detected in 66% (165/
250) of the patients who were investigated by SSCP
analysis (Delaunoy et al. 2001). Even if mutations have
been missed by SSCP in 27% of these patients, as sug-
gested by the present article, 50% of patients who have
no RSK2 defect remain. All of these patients were re-
ferred by various geneticists for mutation screening be-
cause the patients expressed clinical features that were
highly suggestive of CLS. We were able to obtain de-
tailed clinical records for only a minority of these pa-
tients. Since it is not always easy to distinguish CLS
from other syndromes involving mental retardation—
especially in milder cases and cases affecting young
children—it is likely that some of these individuals were
misdiagnosed. In particular, similarities in the clinical
presentation of CLS and X-linked a-thalassemia mental
retardation (ATR-X) have been repeatedly noted. How-
ever, given the high proportion of patients without an
RSK2 mutation, the possibility of locus heterogeneity
should also be taken into consideration. Interestingly, a
patient with a CLS-like phenotype who carried an in-
terstitial deletion on chromosome 10 has recently been
reported (McCandless et al. 2000). This patient was of
short stature, had a coarse facial appearance similar to
that of patients with CLS, and had hand findings that
were characteristic of CLS. In our previous linkage stud-
ies, we used some of the rare known large pedigrees
with CLS, and, at that time, there was no suggestion of
genetic heterogeneity (Hanauer et al. 1988; Biancalana
et al. 1992, 1994). Subsequent investigation revealed
that, in fact, most families with CLS are sporadic cases,
as are 80% of the patients referred to our laboratory
for mutation screening. In addition, in most of the ped-
igrees with two (or, in very rare cases, more) affected
family members, often only one was available for anal-
ysis. Thus, genetic heterogeneity could not be further
investigated by linkage studies.
Although very well documented in a few patients
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only, clinical data have been available for the 26 un-
related patients included in this study. All present with
the major hallmarks of CLS (table 1). One patient
(GW85; age 28 years) exhibited autistic behavior, a fea-
ture that has never been documented in patients with
CLS. In addition, he apparently did not exhibit hypo-
tonia. However, he presented with typical face and hand
anomalies. Prader-Willi syndrome was excluded in this
patient. Review of the available medical records re-
vealed no obvious phenotypic differences between in-
dividuals who did or did not have an RSK2 mutation.
None of the patients who did not have an RSK2 mu-
tation exhibited a-thalassemia and/or urogenital ab-
normalities, excluding at least the classical form ofATR-
X. In addition, examination of photographs (available
for approximately two-thirds of patients) confirmed, in
most of the these patients, the presence of characteristic
large, soft hands and downward-slanting fissures (table
1), two features that are not found in ATR-X. Finally,
mothers of eight patients without an RSK2 mutation
showed mild manifestations (table 1), in contrast to
ATR-X carriers, who usually show no manifestations.
ATR-X has been further excluded, on the basis of mu-
tation screening, in three patients (DZ36, GM49, and
GW85).
All patients except DX43, DX55, DZ36, and DZ37
have sporadic CLS. The affected brother of patient
DX55 died a few years ago, and no blood sample from
the unaffected brother of patient DZ36 could be ob-
tained for analysis. Patient DX43 has one affected
brother, and patient DZ37 has one unaffected brother
and one unaffected sister. In all of the latter patients,
segregation analysis of CLS-flanking markers is com-
patible with linkage to the CLS locus.
It cannot be excluded that some mutations affect par-
ticular RSK2 functions without affecting its enzymatic
activity as assessed in our in vitro test. However, RSK2
cDNA from six patients who showed a typical CLS
phenotype and in whom the RSK2 protein was present
was completely sequenced and did not show any ab-
normality. Thus, our data suggest the existence, in an-
other gene (or genes), of defects that result in a CLS-
like phenotype. Further studies need to be undertaken
before a definitive conclusion about genetic heteroge-
neity can be drawn. Global assessment of gene-expres-
sion levels by use of high-density microarrays that rep-
resent all human genes may be used to identify over- or
underexpressed candidate genes, for more-detailed stud-
ies in these patients.
Acknowledgments
We are grateful to all the families and clinicians whose
participation made this study possible. The work was sup-
ported by grants from the Association Franc¸aise pour la
Recherche contre le Cancer, the Centre National de la Re-
cherche Scientifique, the INSERM, and the Hoˆpital Uni-
versitaire de Strasbourg.
Electronic-Database Information
The accession number and URLs for data in this article are
as follows:
BLAST, http://www.ncbi.nlm.nih.gov/BLAST/ (for human and
mouse databases)
Coffin Lowry Syndrome Mutations Data Base, http://www-
ulpmed.u-strasbg.fr/chimbio/diag/coffin/index.html
MatInspector V2.2: Input Form, http://transfac.gbf.de/cgi-bin/
matSearch/matsearch.pl
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for CLS [MIM #303600])
Welcome to TESS: Transcription Element Search System,
http://www.cbil.upenn.edu/tess/
References
Biancalana V, Briard ML, David A, Gilgenkrantz S, Kaplan J,
Mathieu M, Piussan C, Poncin J, Schinzel A, Oudet C, Han-
auer A (1992) Confirmation and refinement of the genetic
localization of the Coffin-Lowry syndrome locus in Xp22.1-
p22.2. Am J Hum Genet 50:981–987
Biancalana V, Trivier E, Weber C, Weissenbach J, Rowe PS,
O’Riordan JL, Partington MW, Heyberger S, Oudet C, Han-
auer A (1994) Construction of a high-resolution linkagemap
for Xp22.1-p22.2 and refinement of the genetic localization
of the Coffin-Lowry syndrome gene. Genomics 22:617–625
Bjorbaek C, Vik TA, Echwald SM, Yang PY, Vestergaard H,
Wang JP, Graham C, Webb GC, Richmond K, Hansen T,
Erikson RL, George E, Miklos G, Cohen P, Pedersen O
(1995) Cloning of a human insulin-stimulated protein kinase
(ISPK-1) gene and analysis of coding regions and mRNA
levels of the ISPK-1 and the protein phosphatase-1 genes in
muscle from NIDDM patients. Diabetes 44:90–97
Coffin GS, Siris E, Wegienka LC (1966)Mental retardationwith
osteocartilaginous anomalies. Am J Dis Child 112:205–213
Delaunoy JP, Abidi F, Zeniou M, Jacquot S, Merienne K, Pan-
netier S, Schmitt M, Schwartz CE, Hanauer A (2001) Mu-
tations in the X-linked RSK2 gene (RPS6KA3) in patients
with Coffin-Lowry syndrome. Hum Mutat 17:103–116
Gilgenkrantz S, Mujica P, Gruet P, Tridon P, Schweitzer F,
Nivelon-Chevallier A, Nivelon JL, Couillault G, David
A, Verloes A, Lambotte C, Piussan C, Mathieu M (1988)
Coffin-Lowry syndrome: a multicenter study. Clin Genet
34:230–245
Hanauer A, Alembik Y, Gilgenkrantz S, Mujica P, Nivelon-
Chevallier A, Pembrey ME, Young ID, Mandel JL (1988)
Probable localisation of the Coffin-Lowry locus in Xp22.2-
p22.1 by multipoint linkage analysis. Am J Med Genet 30:
523–530
Hunter AG, Partington MW, Evans JA (1982) The Coffin-
Lowry syndrome: experience from four centres. Clin Genet
21:321–335
Jacquot S, Merienne K, De Cesare D, Pannetier S, Mandel JL,
Sassone-Corsi P, Hanauer A (1998) Mutation analysis of the
Zeniou et al.: CLS and RSK2 Mutations 1433
RSK2 gene in Coffin-Lowry patients: extensive allelic het-
erogeneity and a high rate of de novo mutations. Am J Hum
Genet 63:1631–1640
Jacquot S, Zeniou M, Touraine R, Hanauer A (2002) X-linked
Coffin-Lowry syndrome (CLS, MIM 303600, RPS6KA3
gene, protein product known under various names: pp90rsk2,
RSK2, ISPK, MAPKAP1. Eur J Hum Genet 10:2–5
Krawczak M, Cooper DN (1997) The Human Gene Mutation
Database. Trends Genet 13:121–122
Laporte J, Biancalana V, Tanner SM, Kress W, Schneider V,
Wallgren-Pettersson C, Herger F, Buj-Bello A, Blondeau F,
Liechti-Gallati S, Mandel JL (2000) MTM1 mutations in X-
linked myotubular myopathy. Hum Mutat 15:393–409
Lowry B, Miller JR, Fraser FC (1971) A new dominant gene
mental retardation syndrome: association with small stature,
tapering fingers, characteristic facies, and possible hydro-
cephalus. Am J Dis Child 121:496–500
Manouvrier-Hanu S, Amiel J, Jacquot S, Merienne K, Moer-
man A, Coeslier A, Labarriere F, Valle´e L, Croquette MF,
Hanauer A (1999) Unreported RSK2 missense mutation in
two male sibs with an unusually mild form of Coffin-Lowry
syndrome. J Med Genet 36:775–778
McCandless SE, Schwartz S, Morrison S, Garlapati K, Robin
NH (2000) Adult with an interstitial deletion of chromo-
some 10 [del(10)(q25.1q25.3)]: overlap with Coffin-Lowry
syndrome. Am J Med Genet 95:93–98
Merienne K, Jacquot S, Pannetier S, Zeniou M, Bankier A,
Gecz J, Mandel JL, Mulley J, Sassone-Corsi P, Hanauer A
(1999) A missense mutation in RPS6KA3 (RSK2) respon-
sible for non-specific mental retardation. Nat Genet 22:
13–14
Merienne K, Jacquot S, Trivier E, Pannetier S, Rossi A, Scott C,
Schinzel A, Castellan C, Kress W, Hanauer A (1998) Rapid
immunoblot and kinase assay tests for a syndromal form of
X linked mental retardation: Coffin-Lowry syndrome. J Med
Genet 35:890–894
Ohno K, Brengman JM, Felice KJ, Cornblath DR, Engel AG
(1999) Congenital end-plate acetylcholinesterase deficiency
caused by a nonsense mutation and an ArG splice-donor–
site mutation at position 3 of the collagenlike-tail–subunit
gene (COLQ): how does G at position 3 result in aberrant
splicing? Am J Hum Genet 65:635–644
Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T
(1989) Detection of polymorphisms of human DNA by
gel electrophoresis as single-strand conformation poly-
morphisms. Proc Natl Acad Sci USA 86:2766–2770
Park KY, Dalakas MC, Goebel HH, Ferrans VJ, Semino-Mora
C, Litvak S, Takeda K, Goldfarb LG (2000) Desmin splice
variants causing cardiac and skeletal myopathy. JMedGenet
37:851–857
Plomp AS, De Die-Smulders CE, Meinecke P, Ypma-Verhulst
JM, Lissone DA, Fryns JP (1995) Coffin-Lowry syndrome:
clinical aspects at different ages and symptoms in female
carriers. Genet Couns 6:259–268
Temtamy SA, Miller JD, Hussels-Maumenee I (1975) The Cof-
fin-Lowry syndrome: an inherited faciodigital mental retar-
dation syndrome. J Pediatr 86:724–731
Trivier E, De Cesare D, Jacquot S, Pannetier S, Zackai E,
Young I, Mandel JL, Sassone-Corsi P, Hanauer A (1996)
Mutations in the kinase Rsk-2 associated with Coffin-Lowry
syndrome. Nature 384:567–570
Wilson WG, Kelly TE (1981) Brief clinical report: early
recognition of the Coffin-Lowry syndrome. Am J Med
Genet 8:215–220
Young ID (1988) The Coffin-Lowry syndrome. J Med Genet
25:344–348
